Inflammatory Signal Inhibitors for COVID-19 (MATIS)
Conditions: Coronavirus; Covid19; Pneumonia Interventions: Drug: Ruxolitinib; Drug: Fostamatinib; Other: Standard of care Sponsors: Imperial College London; Imperial College Healthcare NHS Trust; Rigel Pharmaceuticals; Novartis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials